deltatrials
Completed PHASE2 INTERVENTIONAL NCT00004582

ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past

A Phase II Study of ABT-378/Ritonavir and Efavirenz in Multiple Protease Inhibitor-Experienced Subjects

Sponsor: ViRx

Conditions HIV Infections
Interventions Efavirenz Lopinavir/Ritonavir
Updated 5 times since 2017 Last updated: Jun 23, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HIV Infections, this trial is completed. The trial is conducted by ViRx and has accumulated 5 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ViRx
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations